Disease: Depressive disorder ×
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0011581
Disease: Depressive disorder
Depressive disorder 		0.380 Biomarker disease BEFREE 182 subjects diagnosed with depression and treated with these drugs were clinically and therapeutically characterized and submitted to the quantification of drug/metabolite plasma concentrations and genotyping of ABCB1, CYP2C9, CYP2C19, and CYP2D6 genes. 31120287 2020
CUI: C0011581
Disease: Depressive disorder
Depressive disorder 		0.380 Biomarker disease BEFREE Influence of CYP2C19 Metabolizer Status on Escitalopram/Citalopram Tolerability and Response in Youth With Anxiety and Depressive Disorders. 30837874 2019
CUI: C0011581
Disease: Depressive disorder
Depressive disorder 		0.380 GeneticVariation disease BEFREE Thus, we studied the effects of polymorphisms of the CYP2C19 gene on raw plasma drug concentrations in Japanese patients with depression. 29570504 2018
CUI: C0011581
Disease: Depressive disorder
Depressive disorder 		0.380 Biomarker disease BEFREE In humans, we found that the absence of CYP2C19 was associated with a bilateral hippocampal volume increase in two independent healthy cohorts (N=386 and 1032) and a lower prevalence of major depressive disorder and depression severity in African-Americans (N=3848). 27895323 2017
CUI: C0011581
Disease: Depressive disorder
Depressive disorder 		0.380 Biomarker disease BEFREE Herein, we present the case of a 29-year-old male with diagnoses of depression and obsessive compulsive disorder who had trialed and failed a dozen psychiatric medications, many of which are subject to metabolism by CYP2D6 and/or CYP2C19, and had most recently been taking clomipramine for approximately 2.5 years. 28470111 2017
CUI: C0011581
Disease: Depressive disorder
Depressive disorder 		0.380 Biomarker disease PSYGENET We report the effect of CYP2C19 and CYP2D6 genotypes on steady state morning concentrations of escitalopram and N-desmethylescitalopram and the ratio of this metabolite to the parent drug in 196 adult patients with depression in GENDEP, a clinical pharmacogenomic trial. 21926427 2012
CUI: C0011581
Disease: Depressive disorder
Depressive disorder 		0.380 Biomarker disease BEFREE We report the effect of CYP2C19 and CYP2D6 genotypes on steady state morning concentrations of escitalopram and N-desmethylescitalopram and the ratio of this metabolite to the parent drug in 196 adult patients with depression in GENDEP, a clinical pharmacogenomic trial. 21926427 2012
CUI: C0011581
Disease: Depressive disorder
Depressive disorder 		0.380 GeneticVariation disease BEFREE The Sequenced Treatment Alternatives to Relieve Depression sample was used to examine the relationship between variations in the CYP2C19 and CYP2D6 genes and remission of depressive symptoms and tolerance to treatment with citalopram. 21192344 2011
CUI: C0011581
Disease: Depressive disorder
Depressive disorder 		0.380 Biomarker disease PSYGENET The Sequenced Treatment Alternatives to Relieve Depression sample was used to examine the relationship between variations in the CYP2C19 and CYP2D6 genes and remission of depressive symptoms and tolerance to treatment with citalopram. 21192344 2011
CUI: C0011581
Disease: Depressive disorder
Depressive disorder 		0.380 Biomarker disease PSYGENET We evaluated whether cytochrome P450 (CYP) poor metabolizer polymorphisms of CYP2D6 and CYP2C19 are relevant for the outcome (measured by length of hospitalization) during treatment with psychotropic medications in patients with depression or schizophrenia. 16812949 2006
CUI: C0011581
Disease: Depressive disorder
Depressive disorder 		0.380 Biomarker disease BEFREE Genetic tests suitable for the routine laboratory are now available for some important metabolizing enzymes (e.g., CYP2D6, CYP2C19) identifying those individuals who are slow or fast metabolizers of certain drugs, many of which are widely used in the treatment of depression (e.g., tricyclic antidepressants). 11412815 2001
CUI: C0011581
Disease: Depressive disorder
Depressive disorder 		0.380 Biomarker disease PSYGENET Genetic tests suitable for the routine laboratory are now available for some important metabolizing enzymes (e.g., CYP2D6, CYP2C19) identifying those individuals who are slow or fast metabolizers of certain drugs, many of which are widely used in the treatment of depression (e.g., tricyclic antidepressants). 11412815 2001